Biogen (BIIB +0.4%) is upgraded to Buy from Neutral by Goldman Sachs, which says the risk/reward...

|About: Biogen Inc. (BIIB)|By:, SA News Editor

Biogen (BIIB +0.4%) is upgraded to Buy from Neutral by Goldman Sachs, which says the risk/reward ratio is still attractive despite the stock's recent outperformance. The firm sees success of its BG-12 multiple sclerosis treatment supporting the current valuation, with "multiple optionalities for upside that are underestimated in Street estimates."